Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 423.08M | 422.67M | 458.30M | 704.27M | 598.37M | 282.25M |
Gross Profit | 291.50M | 292.29M | 318.63M | 519.55M | 481.81M | 179.59M |
EBITDA | 113.24M | 143.39M | 186.77M | 398.96M | 385.70M | 131.78M |
Net Income | -1.28M | 19.52M | 61.59M | 244.07M | 220.78M | 39.28M |
Balance Sheet | ||||||
Total Assets | 1.52B | 1.77B | 1.74B | 1.70B | 1.56B | 1.33B |
Cash, Cash Equivalents and Short-Term Investments | 289.34M | 585.97M | 466.40M | 322.81M | 186.39M | 10.96M |
Total Debt | 351.90M | 650.46M | 655.77M | 662.77M | 758.20M | 775.48M |
Total Liabilities | 642.75M | 893.32M | 895.37M | 916.72M | 1.04B | 802.16M |
Stockholders Equity | 874.17M | 874.40M | 844.97M | 780.96M | 524.30M | 530.67M |
Cash Flow | ||||||
Free Cash Flow | 99.75M | 141.94M | 173.92M | 254.67M | 198.26M | 128.95M |
Operating Cash Flow | 101.11M | 143.07M | 177.53M | 255.32M | 200.03M | 128.97M |
Investing Cash Flow | -4.04M | -4.89M | -3.61M | -2.68M | -6.26M | -1.38B |
Financing Cash Flow | -315.65M | -18.61M | -30.33M | -116.22M | -18.34M | 1.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $23.64B | 20.85 | 50.44% | ― | 1.06% | -0.29% | |
72 Outperform | $1.34B | 7.60 | 28.94% | ― | -0.38% | 35.78% | |
63 Neutral | $1.43B | ― | -58.93% | ― | -10.39% | 14.92% | |
61 Neutral | $17.78B | 13.97 | -5.40% | 3.03% | 1.50% | -15.71% | |
61 Neutral | $6.63B | 8.38 | -52.83% | 2.72% | -0.18% | ― | |
57 Neutral | $973.94M | 77.05 | -0.15% | ― | -3.43% | -102.60% | |
51 Neutral | $896.37M | ― | -15.44% | ― | 11.67% | 31.55% |
On August 20, 2025, Olaplex Holdings, Inc. acquired Purvala Bioscience, a Boston-based biotech company, for $10.5 million. This acquisition marks OLAPLEX’s first since its inception over a decade ago, underscoring its commitment to innovation in the haircare industry. The integration of Purvala’s bioinspired technologies is expected to enhance OLAPLEX’s product offerings, potentially leading to the development of next-generation, science-backed products. This strategic move is anticipated to strengthen OLAPLEX’s position in the market and benefit its stylist community and consumers.
On July 20, 2025, Olaplex Holdings, Inc. announced the election of Jerome Griffith as a Class I director of its Board, with his term set to expire at the 2028 Annual Meeting of Stockholders. Griffith brings a wealth of experience from the retail and consumer goods sectors, having held prominent leadership roles at companies such as Brown Jordan Inc., Lands’ End, Inc., and Tumi Holdings, Inc. This strategic appointment is expected to strengthen Olaplex’s board with Griffith’s extensive industry expertise and leadership background.
On June 10, 2025, Olaplex Holdings, Inc. held its Annual Meeting of Stockholders, where it was announced that Paula Zusi would not be re-elected to the Board of Directors, marking the end of her term. During the meeting, stockholders elected three Class I directors for a three-year term, approved executive compensation for the fiscal year 2024, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year 2025.